A detailed history of New York State Common Retirement Fund transactions in Inhibrx, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 13,882 shares of INBX stock, worth $196,707. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,882
Previous 13,900 0.13%
Holding current value
$196,707
Previous $528,000 8.14%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$32.76 - $39.56 $589 - $712
-18 Reduced 0.13%
13,882 $485,000
Q4 2023

Feb 01, 2024

SELL
$14.5 - $38.0 $855 - $2,242
-59 Reduced 0.42%
13,900 $528,000
Q3 2023

Nov 07, 2023

BUY
$15.75 - $26.31 $1,811 - $3,025
115 Added 0.83%
13,959 $256,000
Q2 2023

Aug 07, 2023

SELL
$16.96 - $27.82 $114,242 - $187,395
-6,736 Reduced 32.73%
13,844 $359,000
Q1 2023

May 02, 2023

BUY
$18.45 - $27.14 $8,118 - $11,941
440 Added 2.18%
20,580 $388,000
Q4 2022

Jan 30, 2023

SELL
$20.18 - $33.33 $343 - $566
-17 Reduced 0.08%
20,140 $496,000
Q3 2022

Nov 08, 2022

SELL
$11.58 - $24.73 $17,439 - $37,243
-1,506 Reduced 6.95%
20,157 $362,000
Q2 2022

Aug 04, 2022

BUY
$8.52 - $25.26 $13,061 - $38,723
1,533 Added 7.62%
21,663 $246,000
Q1 2022

May 05, 2022

BUY
$19.89 - $43.18 $59 - $129
3 Added 0.01%
20,130 $448,000
Q4 2021

Feb 02, 2022

SELL
$26.75 - $46.02 $2,006 - $3,451
-75 Reduced 0.37%
20,127 $879,000
Q3 2021

Nov 02, 2021

SELL
$25.18 - $37.81 $94,701 - $142,203
-3,761 Reduced 15.7%
20,202 $673,000
Q2 2021

Aug 02, 2021

BUY
$14.69 - $27.52 $244,779 - $458,565
16,663 Added 228.26%
23,963 $659,000
Q1 2021

May 11, 2021

BUY
$16.27 - $41.26 $42,302 - $107,276
2,600 Added 55.32%
7,300 $147,000
Q4 2020

Feb 08, 2021

BUY
$15.96 - $50.0 $75,012 - $235,000
4,700 New
4,700 $155,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.